ABSTRACT
Purpose - to evaluate the efficacy of using quersetin in patients with IHD against a background of metabolic syndrome. The authors have examined 55 patients with a chronic form of ischemic heart disease (IHD) with metabolic syndrome (MS), 35 patients out of them (the basic group) against a background of the standard therapy of IHD (ß-adrenoblocker, a nitropreparation, an inhibitor of the angiotensis - converting enzyme, acetylsalicylic acid, statins) received the quercetin agent by means of an infusion. They also analyzed general clinical findings, the parameters of the stale of lipid peroxidation (LPO), the antioxidants defence (AOD) and the oxidative protein modification (OPM) as well as the results of diurnal ECG monitoring. As a result of a course of treatment carried out in the patients of the basic group, the number and duration of ischemic episodes reliably decreased, the number of patients with supraventricular extrasystoles diminished (SE) up to 5% (p<0,05), whereas with isolated ventricular extrasystoles (VE-up to 13% (p<0,05)), with ventricular disturbances of the rhythin of high gradations according to B. Laun (VDRHG) - up to 5% (p<0,05), a significant increase of the lever of reduced hemoglobin (RH) by 13,41% (p<0,05) and a decrease of the content of malonic aldehyde (MA) by 14,9% (p<0,05) have been noted. Qnercetin possesses an antiischemic, antiarrhythmic effect, exerts a regulating influence on vegetative homeostassin, oxidant disturbances, determining its efficacy, while using it in patients with IHD with underlying MS.
Subject(s)
Metabolic Syndrome/drug therapy , Myocardial Ischemia/drug therapy , Quercetin/administration & dosage , Aged , Antioxidants/metabolism , Electrocardiography , Female , Humans , Lipid Peroxidation/drug effects , Male , Metabolic Syndrome/complications , Metabolic Syndrome/pathology , Middle Aged , Myocardial Ischemia/complications , Myocardial Ischemia/pathology , Treatment OutcomeABSTRACT
The subjects, 1048 patients with acute myocardial infarction (AMI), were examined in order to study the chronobiological periodicity of acute coronary catastrophes. The study established that the probability of AMI was the lowest on Sundays and Saturdays, equally higher on Mondays, Wednesdays, and Thursdays, lower on Tuesdays, and the highest on Fridays. Analysis of circannian AMI incidence demonstrates that its probability decreases in September and increases in February, March, May, and June. In August and November, the incidence of different AMI forms differs: transmural forms prevail in August, while large-focal ones prevail in November.
